Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacira Pharmaceuticals reports record revenues and optimistic growth outlook

Pacira Pharmaceuticals had a strong financial performance in 2022, driven by EXPAREL's success and strategic initiatives. While facing challenges in pricing and reimbursement, the company is optimistic about future opportunities for growth through label expansions and market strategies.

Pacira Pharmaceuticals (PCRX) excels in Q1 2023 earnings call

Pacira Pharmaceuticals (PCRX) demonstrated robust financial performance, innovation in non-opioid pain management, and strategic market positioning in Q1 2023.
While facing challenges such as potential surgery trend moderation and pediatric market penetration, the company is leveraging opportunities in expanding EXPAREL use and regulatory advancements.
Overall, Pacira's focus on patient-centric solutions and market expansion initiatives position it well for continued growth and leadership in the pain management sector.

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain The initiative aims to educate clinicians on ultrasound-guided regional approaches to manage postsurgical pain

Pacira BioSciences Launches National Regional Anesthesia Training Initiative with Envision Physician Services

Assertio Therapeutics Inc

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT or PCRX: Which Is the Better Value Stock Right Now?

Fourth quarter preliminary revenue of $122.4 million increased 29% compared with 2018 Fourth quarter preliminary revenue of $122.4 million increased 29% compared with 2018

Pacira BioSciences Reports Full-Year 2019 Preliminary Revenue of $421.0 Million

Pacira's (PCRX) phase IV CHOICE study on its lead drug Exparel in patients undergoing Cesarean section attains the primary as well as key secondary endpoints.

Pacira's (PCRX) Exparel Meets Key Goals in C-Section Study

Avid Bioservices

Endo International

IGM Biosciences Inc

Illumina

IVERIC bio Inc

Kodiak Sciences Inc

Mylan

Neovasc

Pfizer

X4 Pharmaceuticals Inc

After a solid 2019 has seen mixed trading in 2020, and after a massive run over the last decade, many investors are still trying to decide where and how they want their assets positioned in their portfolio.

11 Biotechs and Pharma Stocks Being Given Huge Upside Targets for 2020

EXPAREL TAP block superior to morphine spinal–based standard of care EXPAREL TAP block superior to morphine spinal–based standard of care

EXPAREL Achieves Primary and Key Secondary Endpoints in Phase 4 CHOICE Study in Cesarean Section Patients

Pacira (PCRX) releases positive top-line data from its phase III PLAY study evaluating the pharmacokinetics and safety of Exparel in two patient groups.

Pacira's Late-Stage Study on Exparel Label Expansion Positive

-- New data expected to support expansion of EXPAREL label to include children aged six and over -- -- New data expected to support expansion of EXPAREL label to include children aged six and over --

Pacira BioSciences Announces Positive Results from Phase 3 PLAY Study of EXPAREL® in Pediatric Patients

Pacira (PCRX) focuses on improving sales of its flagship product Exparel. The drug's label expansion programs also look encouraging.

Pacira's Exparel Spurs Growth, Exclusive Reliance a Concern

ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Pacira (PCRX) Up 7.6% Since Last Earnings Report: Can It Continue?

PARSIPPANY, N.J., Nov.  13, 2019  (GLOBE NEWSWIRE) --  Pacira BioSciences, Inc.  (NASDAQ: PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT (9:40AM ET) on Wednesday, November 20, 2019. Live audio of the event can be accessed by visiting the “Events” page of the company’s website at  investor.pacira.com . A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference

Pacira BioSciences, Inc.'s (PCRX) CEO Dave Stack on Q3 2019 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 41.18% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Q3 Earnings Surpass Estimates

Pacira (PCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Pacira (PCRX) Reports Next Week: Wall Street Expects Earnings Growth

Pacira (PCRX) Down 15.3% Since Last Earnings Report: Can It Rebound?

Pacira BioSciences, Inc. (PCRX) CEO David Stack on Q2 2019 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 20.59% and 2.80%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Beats Q2 Earnings and Revenue Estimates

CEO and Chairman of Pacira Biosciences Inc (NASDAQ:PCRX) David M Stack sold 13,115 shares of PCRX on 07/08/2019 at an average price of $42.88 a share.

Pacira Biosciences Inc (PCRX) CEO and Chairman David M Stack Sold $562,371 of Shares

The EMA authorizes Pacira's (PCRX) marketing application for Exparel (bupivacaine liposome injectable suspension) to treat postsurgical pain.

Pacira Gets EMA Acceptance for Pain Management Drug Exparel

Jazz Pharmaceuticals

JAZZ vs. PCRX: Which Stock Is the Better Value Option?

JAZZ or PCRX: Which Is the Better Value Stock Right Now?

Why Is Pacira (PCRX) Down 7.2% Since Last Earnings Report?

JAZZ vs. PCRX: Which Stock Should Value Investors Buy Now?

The small drugmaker posted record sales for its flagship drug in the first quarter.

News for Pacira Pharmaceuticals Stock (PCRX)